New Diabetes Combo Agent Gets FDA Nod
MedPageToday, 2012
The partnership ultimately led to the demise of the relationship between Lilly and Amylin Pharmaceuticals to market other diabetes drugs including weekly exenatide (Bydureon).
Bydureon, a glucagon-like peptide-1 (GLP-1) agonist, had a rocky road to approval, but was by the FDA last week.
The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider.
This Site and third parties who place advertisements on this Site may collect and use information about your visits to this Site and other websites in order to provide advertisements about goods and services of interest to you.
If you would like to obtain more information about these advertising practices and to make choices about online behavioral advertising, please
View rest of article at www.medpagetoday.com «
Related articles
Below are some of our articles related to the article above:
